Preclinical Studies of Chemotherapy Using Histone Deacetylase Inhibitors in Endometrial Cancer
Because epigenetic alterations are believed to be involved in the repression of tumor suppressor genes and promotion of tumorigenesis in endometrial cancers, novel compounds endowed with a histone deacetylase (HDAC) inhibitory activity are an attractive therapeutic approach. In this review, we discu...
Saved in:
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2010-01-01
|
| Series: | Obstetrics and Gynecology International |
| Online Access: | http://dx.doi.org/10.1155/2010/923824 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832564189963485184 |
|---|---|
| author | Noriyuki Takai Hisashi Narahara |
| author_facet | Noriyuki Takai Hisashi Narahara |
| author_sort | Noriyuki Takai |
| collection | DOAJ |
| description | Because epigenetic alterations are believed to be involved in the repression of tumor suppressor genes and promotion of tumorigenesis in endometrial cancers, novel compounds endowed with a histone deacetylase (HDAC) inhibitory activity are an attractive therapeutic approach. In this review, we discuss the biologic and therapeutic effects of HDAC inhibitors (HDACIs) in treating endometrial cancer. HDACIs were able to mediate inhibition of cell growth, cell cycle arrest, apoptosis, and the expression of genes related to the malignant phenotype in a variety of endometrial cancer cell lines. Furthermore, HDACIs were able to induce the accumulation of acetylated histones in the chromatin of the p21WAF1 gene in human endometrial carcinoma cells. In xenograft models, some HDACIs have demonstrated antitumor activity with only few side effects. In this review, we discuss the biologic and therapeutic effects of HDACIs in treating endometrial cancer, with a special focus on preclinical studies. |
| format | Article |
| id | doaj-art-4dbd59723a5f49cf8e518839ddec2aaa |
| institution | Kabale University |
| issn | 1687-9589 1687-9597 |
| language | English |
| publishDate | 2010-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Obstetrics and Gynecology International |
| spelling | doaj-art-4dbd59723a5f49cf8e518839ddec2aaa2025-02-03T01:11:33ZengWileyObstetrics and Gynecology International1687-95891687-95972010-01-01201010.1155/2010/923824923824Preclinical Studies of Chemotherapy Using Histone Deacetylase Inhibitors in Endometrial CancerNoriyuki Takai0Hisashi Narahara1Department of Obstetrics and Gynecology, Faculty of Medicine, Oita University, Hasama-machi, Yufu-shi, Oita 879-5593, JapanDepartment of Obstetrics and Gynecology, Faculty of Medicine, Oita University, Hasama-machi, Yufu-shi, Oita 879-5593, JapanBecause epigenetic alterations are believed to be involved in the repression of tumor suppressor genes and promotion of tumorigenesis in endometrial cancers, novel compounds endowed with a histone deacetylase (HDAC) inhibitory activity are an attractive therapeutic approach. In this review, we discuss the biologic and therapeutic effects of HDAC inhibitors (HDACIs) in treating endometrial cancer. HDACIs were able to mediate inhibition of cell growth, cell cycle arrest, apoptosis, and the expression of genes related to the malignant phenotype in a variety of endometrial cancer cell lines. Furthermore, HDACIs were able to induce the accumulation of acetylated histones in the chromatin of the p21WAF1 gene in human endometrial carcinoma cells. In xenograft models, some HDACIs have demonstrated antitumor activity with only few side effects. In this review, we discuss the biologic and therapeutic effects of HDACIs in treating endometrial cancer, with a special focus on preclinical studies.http://dx.doi.org/10.1155/2010/923824 |
| spellingShingle | Noriyuki Takai Hisashi Narahara Preclinical Studies of Chemotherapy Using Histone Deacetylase Inhibitors in Endometrial Cancer Obstetrics and Gynecology International |
| title | Preclinical Studies of Chemotherapy Using Histone Deacetylase Inhibitors in Endometrial Cancer |
| title_full | Preclinical Studies of Chemotherapy Using Histone Deacetylase Inhibitors in Endometrial Cancer |
| title_fullStr | Preclinical Studies of Chemotherapy Using Histone Deacetylase Inhibitors in Endometrial Cancer |
| title_full_unstemmed | Preclinical Studies of Chemotherapy Using Histone Deacetylase Inhibitors in Endometrial Cancer |
| title_short | Preclinical Studies of Chemotherapy Using Histone Deacetylase Inhibitors in Endometrial Cancer |
| title_sort | preclinical studies of chemotherapy using histone deacetylase inhibitors in endometrial cancer |
| url | http://dx.doi.org/10.1155/2010/923824 |
| work_keys_str_mv | AT noriyukitakai preclinicalstudiesofchemotherapyusinghistonedeacetylaseinhibitorsinendometrialcancer AT hisashinarahara preclinicalstudiesofchemotherapyusinghistonedeacetylaseinhibitorsinendometrialcancer |